Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease

Key Inclusion Criteria:

• Must have the ability to understand and sign a written informed consent form (ICF),which must be obtained prior to initiation of study procedures associated with thistrial

• Must have enrolled in a CD parent protocol, GS-US-419-4015, GS-US-419-4016 orGS-US-419-3895 or any other Gilead/Galapagos sponsored filgotinib treatment studyfor CD

• Females of childbearing potential must have a negative pregnancy test at Day 1 andmust agree to continued monthly pregnancy testing during use of filgotinib treatment

• Female participants of childbearing potential who engage in heterosexual intercoursemust agree to use protocol specified method(s) of contraception for the durationdescribed in the protocol

• Willingness to refrain from live or attenuated vaccines during the study and for 12weeks after last dose of study drug

• Must have completed all required procedures or met protocol specified efficacydiscontinuation criteria in a prior filgotinib treatment study for CD

Key Exclusion Criteria:

• Known hypersensitivity to the study drug

• Any chronic medical condition (including, but not limited to, cardiac or pulmonarydisease, alcohol or drug abuse) that, in the opinion of the Investigator or sponsor,would make the individual unsuitable for the study or would prevent compliance withthe study protocol

• Females of reproductive potential who are unwilling to abide by protocol-specifiedcontraceptive methods as defined in the protocol

• Use of prohibited concomitant medications as outlined in the study protocol

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.